Aura Biosciences

Aura Biosciences, based in Cambridge, MA, is pioneering a novel targeted oncology platform aimed at establishing a new standard of care for various cancer types, with an initial emphasis on ocular and urologic oncology. Utilizing their proprietary Virus-Like Drug Conjugates (VDCs), the company targets a wide range of solid tumors, including the rare and life-threatening choroidal melanoma, for which current treatment options are limited and often result in significant vision loss.

With a commitment to innovation, Aura Biosciences addresses the urgent need for effective therapies that can improve patient outcomes, particularly in cases where existing treatments have proven inadequate. The company's mission is driven by a passion to help cancer patients through the development of advanced therapeutic solutions.

Generated from the website